A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer

Cancer Genetics and Cytogenetics

Volumn 191, Issue 2, 2009, Pages 73-77

  Zhang, Peng ^a   Wei, Qiang ^a   Li, Xiang ^a   Wang, Kunjie ^a   Zeng, Hao ^a   Bu, Hong ^a   Li, Hong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATITIS;

ANIMALS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DNA TRANSPOSABLE ELEMENTS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NF-KAPPA B P50 SUBUNIT; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS; REFERENCE VALUES; RISK FACTORS; SEQUENCE DELETION;

EID: 65549154260     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.01.017     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics, 2008. Cancer J Clin 58 (2008) 71-96
2. Nelson W.G., De Marzo A.M., DeWeese T.L., and Isaacs W.B. The role of inflammation in the pathogenesis of prostate cancer. J Urol 172 (2004) S6-S11 discussion S11-12
3. Nelson W.G., De Marzo A.M., and Isaacs W.B. Prostate cancer. N Engl J Med 349 (2003) 366-381
4. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
5. Palapattu G.S., Sutcliffe S., Bastian P.J., Platz E.A., De Marzo A.M., Isaacs W.B., and Nelson W.G. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26 (2005) 1170-1181
6. De Marzo A.M., DeWeese T.L., Platz E.A., Meeker A.K., Nakayama M., Epstein J.I., Isaacs W.B., and Nelson W.G. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 91 (2004) 459-477
7. Lucia M.S., and Torkko K.C. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J Urol 171 (2004) S30-S34 discussion S35
8. Platz E.A., and De Marzo A.M. Epidemiology of inflammation and prostate cancer. J Urol 171 (2004) S36-S40
9. Voronov E., Shouval D.S., Krelin Y., Cagnano E., Benharroch D., Iwakura Y., Dinarello C.A., and Apte R.N. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100 (2003) 2645-2650
10. Steiner G.E., Newman M.E., Paikl D., Stix U., Memaran-Dagda N., Lee C., and Marberger M.J. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. The Prostate 56 (2003) 171-182
11. Michalaki V., Syrigos K., Charles P., and Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90 (2004) 2312-2316
12. Lu T., Burdelya L.G., Swiatkowski S.M., Boiko A.D., Howe P.H., Stark G.R., and Gudkov A.V. Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci USA 101 (2004) 7112-7117
13. Lu S., and Dong Z. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells. The Prostate 66 (2006) 996-1004
14. Chen F., Castranova V., Shi X., and Demers L.M. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 45 (1999) 7-17
15. Beinke S., and Ley S.C. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. The Biochem J 382 (2004) 393-409
16. Chang J., Zhang C., Tani-Ishii N., Shi S., and Wang C.Y. NF-kappaB activation in human dental pulp stem cells by TNF and LPS. J Dental Res 84 (2005) 994-998
17. Al-Mohanna F., Saleh S., Parhar R.S., and Collison K. IL-12-dependent nuclear factor-kappaB activation leads to de novo synthesis and release of IL-8 and TNF-alpha in human neutrophils. J Leuk Biol 72 (2002) 995-1002
18. Bouma G., and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev 3 (2003) 521-533
19. Dong C., Slattery M.J., Liang S., and Peng H.H. Melanoma cell extravasation under flow conditions is modulated by leukocytes and endogenously produced interleukin 8. Mol Cell Biomech 2 (2005) 145-159
20. Karban A.S., Okazaki T., Panhuysen C.I., Gallegos T., Potter J.J., Bailey-Wilson J.E., Silverberg M.S., Duerr R.H., Cho J.H., Gregersen P.K., Wu Y., Achkar J.P., Dassopoulos T., Mezey E., Bayless T.M., Nouvet F.J., and Brant S.R. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 13 (2004) 35-45
21. Kosoy R., and Concannon P. Functional variants in SUMO4, TAB2, and NFkappaB and the risk of type 1 diabetes. Genes Immun 6 (2005) 231-235
22. Naylor S.L. SNPs associated with prostate cancer risk and prognosis. Front Biosci 12 (2007) 4111-4131
23. Lin S.C., Liu C.J., Yeh W.I., Lui M.T., Chang K.W., and Chang C.S. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett 243 (2006) 47-54
24. Li H., Gao L., Shen Z., Li C.Y., Li K., Li M., Lv Y.J., Li C.X., Gao T.W., and Liu Y.F. Association study of NFKB1 and SUMO4 polymorphisms in Chinese patients with psoriasis vulgaris. Arch Dermatol Res 300 (2008) 425-433
25. MacLennan G.T., Eisenberg R., Fleshman R.L., Taylor J.M., Fu P., Resnick M.I., and Gupta S. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J Urol 176 (2006) 1012-1016
26. Wise G.J., Marella V.K., Talluri G., and Shirazian D. Cytokine variations in patients with hormone treated prostate cancer. J Urol 164 (2000) 722-725
27. Nakashima J., Tachibana M., Horiguchi Y., Oya M., Ohigashi T., Asakura H., and Murai M. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6 (2000) 2702-2706
28. Shariat S.F., Andrews B., Kattan M.W., Kim J., Wheeler T.M., and Slawin K.M. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 58 (2001) 1008-1015
29. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nature Rev 3 (2003) 745-756
30. Yang J., Pan W.H., Clawson G.A., and Richmond A. Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res 67 (2007) 3127-3134
31. Criswell T.L., and Arteaga C.L. Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility. J Biol Chem 282 (2007) 32491-32500
32. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., and Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
33. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., and Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466